Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear

[cafead]

via Roche no longer sees the magic in MAGE-A4. The Swiss drugmaker signaled a retreat from the TCR T-cell target in its first quarter results by putting a pair of phase 1 solid tumor programs out to pasture along with hopes of recouping the $490 million paid out for the assets.

article source